Personalis Price to Sales Ratio 2018-2024 | PSNL
Historical PS ratio values for Personalis (PSNL) over the last 10 years. The current P/S ratio for Personalis as of January 23, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Personalis P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2025-01-23 |
6.15 |
|
3.74 |
| 2024-09-30 |
5.38 |
$1.65 |
3.27 |
| 2024-06-30 |
1.17 |
$1.60 |
0.73 |
| 2024-03-31 |
1.49 |
$1.52 |
0.98 |
| 2023-12-31 |
2.10 |
$1.54 |
1.37 |
| 2023-09-30 |
1.21 |
$1.49 |
0.81 |
| 2023-06-30 |
1.88 |
$1.44 |
1.30 |
| 2023-03-31 |
2.76 |
$1.49 |
1.85 |
| 2022-12-31 |
1.98 |
$1.43 |
1.39 |
| 2022-09-30 |
2.97 |
$1.53 |
1.94 |
| 2022-06-30 |
3.45 |
$1.71 |
2.02 |
| 2022-03-31 |
8.19 |
$1.80 |
4.54 |
| 2021-12-31 |
14.27 |
$1.96 |
7.29 |
| 2021-09-30 |
19.24 |
$2.07 |
9.28 |
| 2021-06-30 |
25.30 |
$2.13 |
11.86 |
| 2021-03-31 |
24.61 |
$2.25 |
10.92 |
| 2020-12-31 |
36.61 |
$2.37 |
15.44 |
| 2020-09-30 |
21.67 |
$2.79 |
7.76 |
| 2020-06-30 |
12.97 |
$2.78 |
4.66 |
| 2020-03-31 |
8.07 |
$4.57 |
1.77 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.396B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
